Biotherapies for Life
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market life-saving biotherapies used to treat serious and rare conditions, including such bleeding disorders as hemophilia and von Willebrand disease.
Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do. We are focused first and foremost on fulfilling our customers' needs, whether by manufacturing and marketing safe and effective products or by researching and developing innovative biotherapies.
What are biotherapies?
Biotherapies differ from chemical-derived pharmaceuticals in many ways. Mainly, biotherapies are not derived from chemicals, but are derived from human plasma or produced as their recombinant equivalents. Biotherapies undergo rigorous safety controls and inspections throughout every step of a yearlong manufacturing process from the collection of plasma to the finished product.
Our products are produced in accordance with US safety and quality standards. The company also operates CSL (formerly ZLB) Plasma, which includes the largest plasma collection networks in the United States.
CSL Behring employs more than 7,000 people in 19 countries who are passionate about safety, quality and the customers we serve. Our extensive research and development and range of support services demonstrate our ongoing commitment to the people who count on our products.
In this section, learn more about our commitment to people with serious and rare conditions, the physicians who treat them and much more:
Therapies
Patient Commitment
Physician Support
Research & Development
Newsroom
Last Updated:
3/29/2010 12:37 PM